
The FDA has advised COVID-19 vaccine manufacturers to develop monovalent shots targeting the XBB.1.5 subvariant, which is currently dominant. This recommendation follows the unanimous suggestion from the FDA's expert panel. Previously, bivalent boosters targeted both the original and Omicron strains. Pfizer/BioNTech, Moderna, and Novavax are already working on updated vaccines to target XBB.1.5.
Like
Save
Share